2026 ASCO Gastrointestinal Cancers Symposium
Colton Jones, M.D., of The University of Texas San Antonio, discusses aspirin for colorectal cancer prevention after presenting research comparing GLP-1s with aspirin at the 2026 ASCO Gastrointestinal Cancers Symposium earlier this month in San Francisco.
Advertisement
Post-hoc analysis shows potential of biomarkers for identifying pancreatic patients who respond to treatment.
People taking glucagon-like peptide 1 (GLP-1) drugs were 36% less likely to develop colorectal cancer than those taking aspirin, according to a real-world, head-to-head study.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
GLP-1 therapy tied to lower mortality and liver decompensation in older adults with MASLD
2
Kaiser’s formulary chief makes his case for a ‘total value’ model on biologics | HSES 2026
3
Health-system pharmacy leaders are being asked to solve a margin problem and it is costing hospitals | HSES 2026
4
The GLP-1 access gap in type 2 diabetes isn’t coverage — it’s physician awareness | HSES 2026
5